Some companies raise capital. Others raise eyebrows. Corus Orthodontists just raised $20M in institutional equity, and the interesting part is not the number. It is the timing, the structure, and the...
Some companies raise capital. Others raise eyebrows. Corus Orthodontists just raised $20M in institutional equity, and the interesting part is not the number. It is the timing, the structure, and the restraint. Founded in 2019 by Dr. Paul Helpard and 18 orthodontists who were tired of watching patient care get boxed in by spreadsheets, Corus has spent 5 years building something quieter and harder to copy. Doctor owned. Doctor led. Growth without surrender. That is a harder song to play, but it lasts longer in the set.
This is Corus’ first institutional equity investment, led by ATB Financial’s private equity arm alongside a prominent Canadian family office. Not tourists. Long term partners. The kind who understand that orthodontics is not about speed, it is about alignment. Financial, clinical, cultural. The company already has access to more than $100M in capital, backed by a $250M credit facility with CIBC, Scotiabank, and ATB Financial. The equity round is not about survival or flash. It is about optionality, liquidity for existing shareholders, and making room at the table for the next generation of Doctor Partners.
Dean Prevost stepped in as CEO in September 2024, bringing a résumé forged in telecom, technology, and large scale integration. Peter Bishop continues to keep the balance sheet sharp as CFO. Dr. Paul Helpard now operates as Founder and Strategic Advisor, which feels less like a step back and more like a widening of the lens. The board, chaired by Alan D. Torrie, blends operators, investors, and practicing orthodontists who actually know what a chairside decision feels like at 4:45 on a Thursday.
Corus is not selling scale as a costume. 65+ Doctor Partners. 75+ locations. 13 U.S. states. 5 Canadian provinces. 2 straight years of double digit organic growth. Those numbers matter, but the model matters more. Cash plus stock. Buy in instead of sell out. Local brands stay local. Doctors retain ownership of patient records. The company handles the gravity so clinicians can focus on the art. That is not rebellion. That is discipline.
This investment will flow into people, practices, and future partners who want equity with their autonomy. It is a signal to orthodontists who want growth without losing their name on the door, and to investors who know healthcare rewards patience more than noise. Corus is not trying to be loud. It is trying to be in tune, and in this market, that might be the most disruptive move of all.